Edition:
United States

Syneron Medical Ltd (ELOS.OQ)

ELOS.OQ on NASDAQ Stock Exchange Global Select Market

10.85USD
26 May 2017
Change (% chg)

$-0.05 (-0.46%)
Prev Close
$10.90
Open
$10.88
Day's High
$10.88
Day's Low
$10.85
Volume
99,796
Avg. Vol
89,914
52-wk High
$11.43
52-wk Low
$6.21

Latest Key Developments (Source: Significant Developments)

Sand Grove Capital reports 5.2 pct stake in Syneron Medical
Wednesday, 10 May 2017 06:38am EDT 

May 10 (Reuters) - Sand Grove Capital Management Llp::Sand Grove Capital Management Llp reports 5.2 percent stake in Syneron Medical Ltd as of April 28 - SEC filing.  Full Article

Syneron Candela announces end of go-shop period
Wednesday, 10 May 2017 06:00am EDT 

May 10 (Reuters) - Syneron Medical Ltd : :Syneron Candela announces end of go-shop period.Syneron says with barclays help, engaged in active and extensive solicitation of 59 potential bidders, during go-shop period.Syneron says this resulted in two potential bidders each negotiating and entering into confidentiality agreement with Syneron Candela.Syneron Candela did not receive any alternative acquisition proposals during "go-shop" period.Syneron says the two parties who entered into confidentiality agreements subsequently confirmed they were not interested in a deal.Syneron says deal is expected to be completed during Q3 of 2017,.  Full Article

Syneron Candela reports agreement to be acquired by funds advised by Apax Partners
Monday, 3 Apr 2017 07:00am EDT 

Syneron Medical Ltd : Syneron Candela announces agreement to be acquired by funds advised by Apax Partners for $11.00/share in cash, representing an approximate value of $397 million . Syneron Medical Ltd - transaction valued at approximately $397 million . Syneron Medical Ltd - Shimon Eckhouse, who owns 7.4 pct of company, has entered into a customary voting agreement .Syneron Medical Ltd - Eckhouse has agreed to vote all of his shares in favor of transaction.  Full Article

Syneron Medical Q2 non-gaap EPS $0.09
Thursday, 4 Aug 2016 07:00am EDT 

Syneron Medical Reports Second Quarter 2016 Revenue Of $75.0 Million And Non : Gaap eps of $0.09 . Q2 revenue $75 million versus i/b/e/s view $75.7 million . Q2 non-gaap earnings per share $0.09 . Q2 earnings per share view $0.06 -- Thomson Reuters I/B/E/S .Q2 earnings per share $0.03.  Full Article

Syneron Medical Ltd says PicoWay Picosecond laser receives U.S. FDA clearance for ultra-short 785nm wavelength
Monday, 25 Jul 2016 09:00am EDT 

Syneron Medical Ltd :Syneron Candela's Picoway Picosecond laser receives U.S. FDA clearance for ultra-short 785nm wavelength.  Full Article

Syneron Candela says announces FDA clearance of its non-invasive fat destruction device
Monday, 18 Jul 2016 09:00am EDT 

Syneron Medical Ltd : Syneron candela announces fda clearance of high energy ultrashape power for fat destruction .Fda clearance is for non-invasive reduction of abdominal circumference via fat cell destruction.  Full Article

Syneron Medical reports Q1 adj. earnings per share $0.04
Thursday, 19 May 2016 07:22am EDT 

Syneron Medical Ltd : Syneron Medical reports first quarter 2016 revenue of $68.7 million . Q1 non-GAAP earnings per share $0.04 . Q1 revenue $68.7 million versus I/B/E/S view $64.4 million .Q1 earnings per share view $0.01 -- Thomson Reuters I/B/E/S.  Full Article

Syneron Medical Ltd gives Q4 2015 revenue outlook above analysts' estimates
Monday, 11 Jan 2016 04:05pm EST 

Syneron Medical Ltd:Sees Total revenue for Q4 2015 is expected to be in the range of $78 to $79 million.Q4 2015 revenue of $75 mln - Thomson Reuters I/B/E/S.  Full Article

Syneron Medical Ltd's Syneron Candela Announces New FDA Clearance for the CO2RE System
Thursday, 5 Nov 2015 09:00am EST 

Syneron Medical Ltd:Says the US Food and Drug Administration (FDA) has granted numerous additional indications for use of the CO2RE CO2device.Saus This clearance, including more than 90 specific indications in total, significantly expands the business opportunity for CO2RE users for high patient demand treatments.Says new indications for use include gynecology applications (including vaginal treatments), wrinkles, scars, and a wide range of dermatology and plastic surgery indications.  Full Article

Syneron Medical Ltd Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser
Monday, 27 Jul 2015 09:00am EDT 

Syneron Medical Ltd:Says it has received Korean Ministry of Food and Drug Safety (MFDS) regulatory clearance for the PicoWay picosecond laser.Says With this regulatory clearance, the Company can fulfill PicoWay orders from its Korean distribution partner, with additional commercial launch activity in Korea anticipated later in the third quarter 2015.  Full Article

More From Around the Web

BRIEF-Sand Grove Capital reports 5.2 pct stake in Syneron Medical

* Sand Grove Capital Management Llp reports 5.2 percent stake in Syneron Medical Ltd as of April 28 - SEC filing Source text - (http://bit.ly/2qZ8itX) Further company coverage: